Menu
Currency
GWAS Study

MEPE loss-of-function variant associates with decreased bone mineral density and increased fracture risk.

Surakka I, Fritsche LG, Zhou W et al.

33097703 PubMed ID
GWAS Study Type
21907 Participants
122 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SI
Surakka I
FL
Fritsche LG
ZW
Zhou W
BJ
Backman J
KJ
Kosmicki JA
LH
Lu H
BB
Brumpton B
NJ
Nielsen JB
GM
Gabrielsen ME
SA
Skogholt AH
WB
Wolford B
GS
Graham SE
CY
Chen YE
LS
Lee S
KH
Kang HM
LA
Langhammer A
FS
Forsmo S
ÅB
Åsvold BO
SU
Styrkarsdottir U
HH
Holm H
GD
Gudbjartsson D
SK
Stefansson K
BA
Baras A
AG
Abecasis GR
HK
Hveem K
WC
Willer CJ
Chapter II

Abstract

Summary of the research findings

A major challenge in genetic association studies is that most associated variants fall in the non-coding part of the human genome. We searched for variants associated with bone mineral density (BMD) after enriching the discovery cohort for loss-of-function (LoF) mutations by sequencing a subset of the Nord-Trøndelag Health Study, followed by imputation in the remaining sample (N = 19,705), and identified ten known BMD loci. However, one previously unreported variant, LoF mutation in MEPE, p.(Lys70IlefsTer26, minor allele frequency [MAF] = 0.8%), was associated with decreased ultradistal forearm BMD (P-value = 2.1 × 10-18), and increased osteoporosis (P-value = 4.2 × 10-5) and fracture risk (P-value = 1.6 × 10-5). The MEPE LoF association with BMD and fractures was further evaluated in 279,435 UK (MAF = 0.05%, heel bone estimated BMD P-value = 1.2 × 10-16, any fracture P-value = 0.05) and 375,984 Icelandic samples (MAF = 0.03%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005). Screening for the MEPE LoF mutations before adulthood could potentially prevent osteoporosis and fractures due to the lifelong effect on BMD observed in the study. A key implication for precision medicine is that high-impact functional variants missing from the publicly available cosmopolitan panels could be clinically more relevant than polygenic risk scores.

21,907 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

21907
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Norway
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.